Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended December 31, 2017 (quarter ended December 31; fiscal-year quarter designation may differ from the calendar-quarter metadata). Amounts are in U.S. dollars.
Business context
Vistagen is a clinical-stage biopharmaceutical company with no approved products and no recurring product revenue. Its lead candidate, oral AV-101, was in Phase 2 development, primarily as an adjunctive treatment for major depressive disorder (MDD). The company also pursues stem-cell and drug-rescue research through VistaStem and has sublicensed certain cardiac stem-cell technology to BlueRock Therapeutics.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2017 | Three months ended Dec. 31, 2016 | Nine months ended Dec. 31, 2017 | Nine months ended Dec. 31, 2016 |
|---|---|---|---|---|
| Revenue | $0 | $1.25 million | $0 | $1.25 million |
| Research and development | $1.60 million | $1.61 million | $5.12 million | $4.04 million |
| General and administrative | $1.27 million | $2.28 million | $5.00 million | $4.91 million |
| Net loss | $3.00 million | $2.64 million | $10.27 million | $7.71 million |
| Net loss attributable to common stockholders | $3.47 million | $2.88 million | $11.23 million | $8.84 million |
| Basic and diluted loss per share | $0.25 | $0.34 | $1.03 | $1.23 |
- The prior-period revenue was a one-time $1.25 million BlueRock sublicense payment; the filing reports no recurring revenue. Gross margin is not meaningful for this pre-commercial company.
- Nine-month operating expenses rose to $10.12 million from $8.95 million, and net loss increased. R&D rose about 27%, principally reflecting AV-101 development and trial preparation. Quarterly G&A fell about 44%, mainly because the prior-year quarter included larger professional-services and warrant-modification expenses.
- Cash and cash equivalents were $13.03 million at December 31, 2017, versus $2.92 million at March 31, 2017. Current assets were $13.97 million and current liabilities $1.33 million; total liabilities were $3.98 million.
- For the nine months, operating cash use was $6.45 million, investing cash use was $1,600, and financing provided $16.57 million. Financing included public offerings and private placements.
- Notes payable were $43,700, all current; capital lease obligations totaled $12,600. The balance sheet also included $2.34 million of accrued Series B preferred dividends. The company reported no off-balance-sheet arrangements.
Material changes, outlook, and notable items
- In December 2017, Vistagen raised $15.0 million gross, approximately $13.6 million net, in an offering of 10.0 million common shares and warrants for up to 10.0 million shares. The September 2017 offering generated approximately $2.0 million net. The company also received approximately $1.1 million from private placements during the nine-month period.
- Common shares outstanding increased from 8.97 million at March 31 to 22.72 million at December 31, 2017; 22.90 million were reported outstanding as of February 9, 2018. Warrants, options, and convertible preferred stock create additional potential dilution.
- The December offering triggered a down-round provision on September Series A2 warrants, reducing their exercise price to $0.001. The company recorded a $199,200 deemed dividend; holders exercised the remaining warrants in January 2018 for nominal proceeds. The filing says no outstanding warrants then retained down-round protection.
- Vistagen recorded a $135,000 loss when settling $526,500 of CMO accounts payable with 500,000 shares and a cash payment. It also recognized $1.39 million of stock-based compensation for the nine months.
- The FDA authorized the planned 180-patient AV-101 Phase 2 adjunctive MDD study in October 2017 and granted Fast Track Designation in December. Management planned to start the study in Q1 2018 and expected top-line results in the first half of 2019. The NIMH-funded Phase 2 monotherapy study was ongoing; the company stated it bore no cost other than supplying trial material.
- Management said the December cash balance was expected to fund planned operations for at least 12 months after the financial statements were issued. It also anticipated seeking additional capital for later-stage AV-101 work and operations in 2019 and beyond, and warned that financing may not be available on acceptable terms or at all. The filing describes continuing losses and negative operating cash flows and identifies going-concern risk.
- Management expected AV-101 trial expenses to increase materially as the Phase 2 study commenced. It cited clinical efficacy and safety, trial execution, manufacturing supply, regulatory approval, competition, intellectual-property protection, and access to financing as significant risks. Fast Track status does not assure faster review or approval.
- Disclosure controls were assessed as effective, but two previously identified material weaknesses in financial reporting controls—segregation of duties and accounting software functionality—remained unremediated. The filing reported no legal proceedings.
Investor verification checklist
- Confirm the AV-101 Phase 2 study launch, enrollment progress, safety findings, and timing of results against subsequent filings.
- Track cash burn and financing needs against management’s stated runway, particularly the funding required for Phase 3 development and operations beyond 2018.
- Review share and warrant dilution, including exercise terms, preferred-stock conversion rights, and subsequent option grants.
- Assess whether AV-101 manufacturing supply and the new production process support the clinical program, and verify the status and scope of relevant patents.
- Check whether the material weaknesses in internal controls have been remediated and whether financial reporting remains reliable.